Fate Therapeutics, Inc.
FATE Real Time Price USDRecent trades of FATE by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Daniel S. Goldman House / D | Sale $1,001 - $15,000 | Jan. 31, 2023 |
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by FATE's directors and management
Government lobbying spending instances
-
$20,000 Apr 11, 2012 Issue: None
-
$20,000 Jan 10, 2012 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Defense
-
$20,000 Oct 12, 2011 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Defense
-
$20,000 Jul 18, 2011 Issue: Defense Budget/Appropriations Medical/Disease Research/Clinical Labs
-
$20,000 Apr 10, 2011 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Defense
-
$20,000 Jan 12, 2011 Issue: Medical/Disease Research/Clinical Labs Defense Budget/Appropriations
-
$25,000 Oct 14, 2010 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Defense
-
$25,000 Jul 17, 2010 Issue: Budget/Appropriations Defense Medical/Disease Research/Clinical Labs
-
$20,000 Apr 18, 2010 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Defense
-
$20,000 Jan 14, 2010 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Defense
-
$20,000 Oct 17, 2009 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Veterans Defense
-
$20,000 Jul 18, 2009 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Defense Veterans
-
$20,000 Apr 14, 2009 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations
Estimated quarterly lobbying spending
New patents grants
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of FATE in WallStreetBets Daily Discussion
Recent insights relating to FATE
Recent picks made for FATE stock on CNBC
ETFs with the largest estimated holdings in FATE
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view FATE Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.